182 related articles for article (PubMed ID: 19522047)
41. [New therapies turn oral steroids into reserve agents].
Einecke D
MMW Fortschr Med; 2016 Jun; 158(11):79. PubMed ID: 27271427
[No Abstract] [Full Text] [Related]
42. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis.
Haldar P; Brightling CE; Singapuri A; Hargadon B; Gupta S; Monteiro W; Bradding P; Green RH; Wardlaw AJ; Ortega H; Pavord ID
J Allergy Clin Immunol; 2014 Mar; 133(3):921-3. PubMed ID: 24418480
[No Abstract] [Full Text] [Related]
43. Mepolizumab: First Global Approval.
Keating GM
Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
[TBL] [Abstract][Full Text] [Related]
44. Anti-IgE or Anti-IL5: That Is the Question.
Israel E; Panettieri RA
J Allergy Clin Immunol Pract; 2018; 6(3):782-784. PubMed ID: 29150253
[No Abstract] [Full Text] [Related]
45. Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma.
Katz LE; Gleich GJ; Hartley BF; Yancey SW; Ortega HG
Ann Am Thorac Soc; 2014 May; 11(4):531-6. PubMed ID: 24606022
[TBL] [Abstract][Full Text] [Related]
46. Benralizumab: for asthma, not yet for COPD.
Fabbri LM
Lancet Respir Med; 2014 Nov; 2(11):862-863. PubMed ID: 25306558
[No Abstract] [Full Text] [Related]
47. Mepolizumab-based therapy in asthma: an update.
Walsh GM
Curr Opin Allergy Clin Immunol; 2015 Aug; 15(4):392-6. PubMed ID: 26110690
[TBL] [Abstract][Full Text] [Related]
48. Reslizumab and eosinophilic asthma: one step closer to phenotype-directed therapy?
McCallister JW
Am J Respir Crit Care Med; 2011 Nov; 184(10):1096-7. PubMed ID: 22086982
[No Abstract] [Full Text] [Related]
49. [Biotherapies for the treatment of asthma: are they the treatment of the future?].
Tonnel AB; Denis G; Lelong J
Rev Mal Respir; 2006 Sep; 23(4 Pt 2):10S44-10S48. PubMed ID: 17127963
[No Abstract] [Full Text] [Related]
50. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial.
Straumann A; Conus S; Grzonka P; Kita H; Kephart G; Bussmann C; Beglinger C; Smith DA; Patel J; Byrne M; Simon HU
Gut; 2010 Jan; 59(1):21-30. PubMed ID: 19828470
[TBL] [Abstract][Full Text] [Related]
51. Anti-interleukin-5 antibody therapy in eosinophilic diseases.
Simon D; Braathen LR; Simon HU
Pathobiology; 2005; 72(6):287-92. PubMed ID: 16582580
[TBL] [Abstract][Full Text] [Related]
52. Bleomycin-induced pulmonary fibrosis is independent of eosinophils.
Hao H; Cohen DA; Jennings CD; Bryson JS; Kaplan AM
J Leukoc Biol; 2000 Oct; 68(4):515-21. PubMed ID: 11037973
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of pulmonary eosinophilia and hyperreactivity by antibodies to interleukin-5.
Egan RW; Athwahl D; Chou CC; Emtage S; Jehn CH; Kung TT; Mauser PJ; Murgolo NJ; Bodmer MW
Int Arch Allergy Immunol; 1995; 107(1-3):321-2. PubMed ID: 7613159
[TBL] [Abstract][Full Text] [Related]
54. The neutralization of interleukin-5 as a therapeutic concept in allergic inflammation.
Simon HU
Sarcoidosis Vasc Diffuse Lung Dis; 2002 Mar; 19(1):25-8. PubMed ID: 12002381
[TBL] [Abstract][Full Text] [Related]
55. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700.
Kim YJ; Prussin C; Martin B; Law MA; Haverty TP; Nutman TB; Klion AD
J Allergy Clin Immunol; 2004 Dec; 114(6):1449-55. PubMed ID: 15577851
[TBL] [Abstract][Full Text] [Related]
56. Improved small airway dysfunction in severe asthma with clinical remission by anti-interleukin-5/interleukin-5 receptor α.
Akamatsu T; Shirai T; Okawa K; Hirai K
Ann Allergy Asthma Immunol; 2024 May; 132(5):648-650. PubMed ID: 38360105
[No Abstract] [Full Text] [Related]
57. Targeting cytokines in asthma therapy: round one.
Boushey HA; Fahy JV
Lancet; 2000 Dec 23-30; 356(9248):2114-6. PubMed ID: 11191533
[No Abstract] [Full Text] [Related]
58. Eosinophils and airway hyper-responsiveness.
Lipworth BJ
Lancet; 2001 May; 357(9266):1446. PubMed ID: 11360949
[No Abstract] [Full Text] [Related]
59. Anti-IL-5 and hypereosinophilic syndromes.
Sutton SA; Assa'ad AH; Rothenberg ME
Clin Immunol; 2005 Apr; 115(1):51-60. PubMed ID: 15870021
[TBL] [Abstract][Full Text] [Related]
60. Mepolizumab treatment for asthma.
Robinson DS
Expert Opin Biol Ther; 2013 Feb; 13(2):295-302. PubMed ID: 22998420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
